Voyager Therapeutics Inc (NASDAQ:VYGR) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Voyager Therapeutics Inc (NASDAQ:VYGR) have been given an average rating of “Buy” by the twelve ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $27.00.

Several research analysts recently commented on VYGR shares. Morgan Stanley boosted their price target on Voyager Therapeutics from $21.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, July 12th. BidaskClub cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday. Wedbush boosted their price target on Voyager Therapeutics from $27.00 to $36.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 18th. Nomura boosted their price target on Voyager Therapeutics from $26.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Voyager Therapeutics in a research note on Monday, May 6th.

Shares of VYGR traded down $0.06 during midday trading on Wednesday, reaching $20.46. 14,530 shares of the company were exchanged, compared to its average volume of 342,665. The company’s 50-day moving average is $25.18. The stock has a market capitalization of $772.69 million, a P/E ratio of -7.44 and a beta of 2.55. Voyager Therapeutics has a 1-year low of $7.76 and a 1-year high of $28.79.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.81) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.65 by ($1.46). Voyager Therapeutics had a negative return on equity of 129.67% and a negative net margin of 804.55%. The business had revenue of $5.20 million during the quarter, compared to analyst estimates of $3.00 million. As a group, sell-side analysts predict that Voyager Therapeutics will post -2.95 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. Clearbridge Investments LLC increased its holdings in Voyager Therapeutics by 93,030.6% in the first quarter. Clearbridge Investments LLC now owns 379,973 shares of the company’s stock valued at $7,273,000 after buying an additional 379,565 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Voyager Therapeutics by 28.0% in the second quarter. JPMorgan Chase & Co. now owns 326,643 shares of the company’s stock valued at $8,590,000 after buying an additional 71,451 shares during the last quarter. Geode Capital Management LLC increased its holdings in Voyager Therapeutics by 23.1% in the fourth quarter. Geode Capital Management LLC now owns 287,264 shares of the company’s stock valued at $2,700,000 after buying an additional 53,888 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in Voyager Therapeutics by 10.6% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 202,682 shares of the company’s stock valued at $3,879,000 after buying an additional 19,481 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in Voyager Therapeutics by 96.3% in the fourth quarter. Deutsche Bank AG now owns 146,233 shares of the company’s stock valued at $1,374,000 after buying an additional 71,736 shares during the last quarter. 73.92% of the stock is owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Recommended Story: Insider Trading – What You Need to Know

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.